[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587054":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":51,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":74,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Interrupted Sedentary Time Intervention","EXPERIMENTAL","The first 3 participants enrolled with be placed into the intervention group. After this, participants will be randomized in a group allocation ratio of 2:1 using permuted blocked design with varying block size and stratified by treatment plan. 14 participants will complete:\n\n* Baseline visit\n* Standard of care chemotherapy treatment regimen\n* Daily exercise sessions in-clinic up to 4x weekly and at home 6 days per week\n* Week 14 post-intervention visit",[13],"Behavioral: Interrupted Sedentary Time Intervention",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care Control Group","NO_INTERVENTION","Participants will be randomized in a group allocation ratio of 2:1 using permuted blocked design with varying block size and stratified by treatment plan. 7 participants will complete:\n\n* Baseline visit\n* Standard of Care chemotherapy treatment regimen\n* Week 14 visit\n* Participants will be offered Fitbit activity tracker and resistance bands at the end of the study.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"BEHAVIORAL","A 12-week, semi-supervised exercise intervention comprised of reminder prompts, counseling, and activities of walking, cycling, and resistance band exercise for at-home and in-clinic settings. Supervision will be under an exercise trainer. Resistance bands, Libre Pro continuous blood sugar monitor, and Fitbit and ActivPAL trackers will be provided to participants.",[9],[25],{"name":26,"affiliation":5,"role":27},"Christina Dieli-Conwright, MD, PhD","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},"CONTACT","617-582-8321","ChristinaM_Dieli-Conwright@dfci.harvard.edu",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Dana Farber Cancer Institute","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-71.05977,42.35843,{"lat":46,"lon":45},[49,50],{"name":26,"role":30,"phone":31,"phoneExt":18,"email":32},{"name":26,"role":27,"phone":18,"phoneExt":18,"email":18},{"type":27,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Christina Dieli-Conwright, PhD","Principal Investigator","100587054","interrupting-sedentary-time-to-improve-cardiometabolic-health-and-toxicity-in-patients-with-lymphoma-receiving-chemotherapy-the-istand-trial-100587054",false,"NCT06923397","Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign informed consent prior to any study- related procedures.\n* Patients diagnosed with lymphoma.\n* Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.\n* Aged ≥18 years; due to the rarity of the disease in those \\\u003C18 years, this age bracket will not be included.\n* Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.\n* Have physician clearance to participate in exercise.\n* Speak English.\n* Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.\n* Access to a phone that can receive text messages.\n\nExclusion Criteria:\n\n* Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.\n* Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.\n* Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.\n* Patients currently taking weight loss drugs.\n* Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.\n* Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.","ALL","18 Years",{"count":63,"type":64},24,"ESTIMATED","INTERVENTIONAL",[67],"NA","This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.",[70,71,72,73],"Lymphoma","Lymphoma, Hodgkin","Lymphoma, Non-Hodgkin","Sedentary Behavior",[70,75,71,72,76,73],"Hodgkin Lymphoma","Non-Hodgkin Lymphoma","2026-04-09",{"date":79,"type":80},"2026-04-13","ACTUAL",{"date":82,"type":80},"2025-06-05",{"date":84,"type":64},"2026-12-31",{"name":5,"class":6},1]